Drug Trial Radar · NCT05512208
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
Last checked: Nov 19, 2026Latest source record: Oct 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
55
Planned (sponsor's estimate)
Start
Feb 6, 2023
Primary completion
Dec 2027
Study completion Dec 2029
Sponsor
- Lead sponsor
- University of OklahomaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Verastem, Inc.
- First posted
- Aug 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or solid gynecological cancer.
Conditions
- Endometrioid Cancer
- Mucinous Ovarian Cancer
- High Grade Serous Ovarian Cancer
- Cervical Cancer
- Solid Tumor
Interventions
Avutometinib (VS-6766) + defactinibDrug
Avutometinib (VS-6766): will be administered at 3.2 mg orally twice a week Defactinib: will be administered at 200 mg orally twice a day (BID). Treatment will be for 3 weeks, followed by a 1-week rest period, in each 4-week (28 day) cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Patients with objective response rateTime frame: 2 years
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
AdventHealth
Orlando, Florida · Recruiting
Louisiana State University Medical Center New Orleans
New Orleans, Louisiana · Recruiting
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico · Recruiting
Stephenson Cancer Center
Oklahoma City, Oklahoma · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.